Thursday, October 8, 2020

Whither Aducanumab?

The rumor I heard two weeks ago was that it will be a few months before we hear anything from the FDA on approving Biogen's application for approval of aducanumab, but I don't know exactly what that means.  Is that when they will begin their work, or is that when we should expect a conclusion?

In any event, we have just learned that they will at least begin their work very soon -- November 6.  This will include, among other things, public hearings.  This is what I learned from this article.

Aducanumab is not a cure for Alzheimer's disease, but, if it lives up to expectations, it is a major breakthrough that can give a measure of relief to many families and to the healthcare and elder care systems. 

No comments:

Post a Comment

And it gets worse ... or does it?

I've remarked before that, when I speak on the diet aspects of the Dementia Toolkit, I hear groans ... notably, when I talk about avoidi...